Invion Limited (ASX:IVX)

Market Cap	10.58M
Revenue (ttm)	1.47M
Net Income (ttm)	-6.79M
Shares Out	91.98M
EPS (ttm)	-0.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	155,244
Average Volume	137,616
Open	0.1150
Previous Close	0.1150
Day's Range	0.1150 - 0.1200
52-Week Range	0.0780 - 0.4300
Beta	0.68
RSI	62.31
Earnings Date	May 29, 2025

About Invion

Invion Limited, a clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, and solid cancers, such as lung, ovarian, anogenital, and glioblastoma multiforme cancers. It has a research and development agreement with Hudson Institute of Medical Research to develop a novel photosensitiser for the treatment of a range of cancers; and research agreement with P...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 4
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IVX

Financial Performance

In 2024, Invion's revenue was 3.69 million, a decrease of -10.00% compared to the previous year's 4.10 million. Losses were -5.63 million, 248.5% more than in 2023.